Better health.
Within reach.
Every day.
Meet the Management Series - Branded
June 2021
Disclaimer
Save to the extent required by law, neither Hikma Pharmaceuticals PLC nor any of its affiliates (Hikma), nor any other party, is under any duty to update or inform you of any changes to such
information. In particular, it should be noted that the financial information relating to Hikma contained in this document may not have been audited and in some cases is based on management information and estimates.
No reliance may be placed for any purposes whatsoever on the information contained in this document or on its completeness. No representation or warranty, express or implied, is given by or on behalf of Hikma or its directors, officers or employees, advisors or any other person as to the accuracy or completeness of the information or opinions contained in this document and no liability whatsoever is accepted for any such information or opinions or any use which may be made of them.
Certain statements in this presentation, are forward-looking statements, including under the US federal securities laws, including the Private Securities Litigation Reform Act of 1995. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Any forward-looking statements made by or on behalf of Hikma speak only as of the date they are made and are based upon the knowledge and information available to the directors on the date of this presentation.
Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Hikma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak as only of the date of this presentation.
By participating in, listening to or accessing this document or by accepting any copy of this document, you agree to be bound by the foregoing limitations.
All names, logos, and trademarks are properties of their respective owners and are used for identification purposes only.
Hikma Pharmaceuticals PLC | 2 |
Agenda and speakers
2:00 - 2:05pm
2:05 - 2:15pm
2:15 - 2:20pm
2:20 - 2:25pm
2:25 - 2:30pm
2:30 - 3:00pm
Welcome
Branded overview
Commercial,
products & partnership
Manufacturing,
R&D & pipeline
Wrap up
Q&A
Siggi Olafsson | ||
Mazen Darwazah | ||
Siggi Olafsson | Mazen Darwazah | |
Masoud Abdelmajid | CEO | President of MENA & |
Executive Vice Chairman | ||
Ma'moon Araidah | ||
Mazen Darwazah | ||
Masoud Abdelmajid | Ma'moon Araidah | |
VP - Egypt | VP - Algeria & Morocco | |
Hikma Pharmaceuticals PLC | 3 |
Branded - A leader in the MENA region
2020 revenue
2020 core operating profit contribution1
Injectables | Generics | Branded |
42% | 32% | 26% |
57% | 24% | 19% |
1 Core operating profit is $566 million. Before unallocated corporate costs of $98 million and operating profit from Other business of zero, core operating profit contribution from business segments is $664 million
Hikma Pharmaceuticals PLC | 4 |
Branded
Mazen Darwazah
President of Branded
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Hikma Pharmaceuticals plc published this content on 22 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 June 2021 11:06:03 UTC.